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DOPAMINE HAS A MARKED natriuretic and diuretic action in human, rats, and other species (14) , and the hormone is clinically useful for treatment of shock and heart failure because of these properties (18, 27) . Although the hemodynamic effects of dopamine may be the major determinant of excretory changes, direct actions of exogenous and endogenous dopamine on the nephron are also important (2, 14, 23, 37) . Renal dopamine excretion has been shown to increase in proportion to the natriuresis produced by a salt load (18, 27) , and both the natriuresis and dopamine excretion are diminished by inhibition of renal dopamine synthesis (14) . It is now widely accepted that the source of this dopamine is not the renal nerves but that the dopamine is synthesized primarily by proximal tubules, which possess the necessary metabolic pathways (14) , and that this dopamine acts as an autocrine or paracrine regulator of Na ϩ reabsorption (14, 36) .
Most studies of the tubular effects of dopamine have centered on the proximal tubule where dopamine inhibits volume reabsorption by inhibiting both the activity of the Na ϩ /H ϩ antiporter and the Na-K-ATPase (7, 12, 13, 14) . These effects of dopamine in the proximal tubule are mediated by the D 1A dopamine receptor isoform in rats and mice (equivalent to the human D 1 receptor). This receptor is coupled to the G protein, G s , which stimulates cAMP production and inhibits the Na ϩ /H ϩ antiporter (6, 12, 14) . The D 1A receptor is also coupled to phospholipase A 2 (PLA 2 ) and phospholipase C activation, which inhibits Na-K-ATPase activity (14, 30) .
Several studies have shown that the normal inhibitory action of dopamine on salt and water reabsorption by the kidney is important in the maintenance of normal blood pressure (14) . For example, Albrecht et al. (1) showed that defective coupling of the D 1A receptor to the inhibition of the Na ϩ /H ϩ antiporter in renal proximal tubules cosegregated with hypertension in the F2 generation of crosses between spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. The same investigators showed that mice lacking functional D 1A receptors had elevated systolic and diastolic blood pressures that were greater in the mice that were homozygous than in those that were heterozygous for the defective receptor gene (1) .
Dopamine also inhibits Na ϩ and water reabsorption in the cortical collecting duct (CCD). In the isolated perfused rabbit CCD, Muto et al. (23) showed that dopamine inhibited the increase in osmotic water permeability (P f ) with arginine vasopressin (AVP) and ascribed this effect to a D 2 dopamine receptor, because it could be prevented or reversed by metoclopramide, an inhibitor of members of the D 2 family of dopamine receptors. (At the time, there was no subclassification of D 2 receptors; so any of them, which includes the D 2 , D 3 , and D 4 isoforms, could have been inhibited.) Binding studies and RT-PCR have demonstrated both D 2 -type and D 1 -type receptors (D 1A and D 1B in rat and mouse) in glomeruli and medullary tissue as well as in proximal tubules (10, 14) ; however, it has not been possible to demonstrate the presence of D 2 -type receptors by Northern blot of mRNA from renal cortex (11) , possibly because of their low relative abundance.
We have recently examined the effects of dopamine in the isolated perfused rat CCD and found that it inhibited AVP-dependent P f , as well as the lumen-to-bath flux of Na ϩ (J Na ) and transepithelial voltage (V T ) (37) . When P f and J Na were stimulated by 8-(4-chlorophenylthio)-cAMP, dopamine had no effect, which we interpreted to indicate that the action was mediated by a D 2 -type receptor that was coupled to inhibition of adenylyl cyclase by the G i -type G-protein.
In contrast, Satoh et al. (30, 31) have shown that dopamine increases cAMP production in isolated but nonperfused rat CCD via a D 1 -type receptor, which in turn inhibits Na-K-ATPase activity and might be expected to inhibit J Na . In our studies, we found no effect of the D 1 agonists fenoldopam or SKF-81297 on P f or J Na in the presence or absence of AVP, and the effects of dopamine in the presence of AVP were not reversed by the D 1A antagonist Sch-23390 (37) . The D 2 receptorspecific agonist quinpirole also had no effect on the AVP-dependent V T , and the D 2 and D 3 antagonists domperidone and pimozide did not reverse the dopamine inhibition of V T . Only clozapine, a D 4 -specific antagonist, reversed the effects of dopamine on AVPdependent P f , J Na , and V T (37) . In more recent studies in which cAMP generation was measured in intact rat CCD segments, we found that neither dopamine nor fenoldopam stimulated cAMP production in the absence of AVP. On the other hand, dopamine inhibited AVP-dependent cAMP production by ϳ50%, and this inhibition was reversed by clozapine but not by other D 2 -and D 1 -type antagonists (16) . Thus we concluded that the inhibition of AVP-dependent transepithelial Na ϩ and water transport in the rat CCD by dopamine is mediated via a D 4 receptor.
The present studies were undertaken to determine, using RT-PCR and immunohistochemistry, whether D 1A and D 4 dopamine receptors are expressed in the rat CCD and thus, ultimately, to identify the alternate signaling pathways that may be involved in the regulation of Na ϩ and water transport in this nephron segment.
METHODS
Male Sprague-Dawley rats obtained from Harlan Sprague Dawley (Indianapolis, IN) were maintained on a regular 16% protein rodent diet (diet 8746; Teklad, Madison, WI) containing 0.35% NaCl (measured in our laboratory) for 2-4 wk, at which time they were 5-7 wk of age and weighed 70-170 g. Other rats, used for isolated perfused CCD experiments, were maintained on this diet and also were treated with deoxycorticosterone (DOC) to increase the Na ϩ reabsorptive rate and thus increase the ability to observe change is V T with luminal dopamine treatment (4) . A slow-release (3-wk) pellet containing 2.5 mg of DOC was implanted subcutaneously in the dorsum of these rats. It should be noted that DOC treatment was used only for experiments with isolated perfused renal tubules and not for those involving RT-PCR, immunohistochemistry, or immunoblotting.
In the RT-PCR experiments we initially microdissected CCD segments from slices of kidney that had been digested with collagenase according to standard methods (see Ref. 34) and obtained samples of 2-20 mm total tubule length. Although we have been able to amplify mRNA from Յ2 mm of CCD for several targets, we could not easily obtain sufficient quantities to detect mRNA for the apparently less abundant dopamine D 1A and D 4 receptors. During this time, we developed a modified collagenase digestion technique for dissecting larger numbers of nephron segments, which has been described in detail (34) .
Here, we will describe the method in brief. After a kidney was removed and the capsule was stripped away, a ThomasStadie-Riggs tissue slicer (Thomas Scientific, Swedeboro, NJ) was used to cut sections 0.5-to 1.0-mm thick tangential to the cortical surface. The slices were then torn into small chunks. These pieces of tissue were incubated in 2 ml of warm MEM containing 0.5 mg/ml of class 2 collagenase, 5 mM glycine, 50 U/ml DNase, and 48 µg/ml soybean trypsin inhibitor in a 20-ml scintillation vial. [All reagents were from Sigma Chemical (St. Louis, MO), with the exception of the collagenase (catalog no. 4176), which was obtained from Worthington Biochemical (Freehold, NJ)]. The cortical pieces were briefly (Ͻ5 s) and very gently agitated by hand and incubated without shaking at 37°C. At ϳ15-min intervals, the suspension was gently agitated, and the cloudy, tubule-rich supernatant was poured off the sedimented tissue into a 5 ml ice-cold test tube. The tubule segments sedimented rapidly in the test tube, and the supernatant was removed with a Pasteur pipette and replaced with 2 ml of ice-cold, enzyme-free MEM containing 1% BSA. CCD segments were manually sorted at 4°C from the resulting suspension of nephron segments. Using this method, one investigator could sort over 100 mm of CCD segments from a single kidney within 1-2 h.
Groups of sorted CCD segments were transferred in 5-10 µl of the enzyme-free MEM into 1.0 ml guanidinium/acid phenol solution for RNA extraction according to the TRIzol (Life Technologies, Gaithersburg, MD) protocol. RNA was also extracted from rat brain and atria to serve as positive controls, because it is known that both D 1A and D 4 isoforms are expressed in these tissues (22, 25, 44) . The total RNA was treated with DNase I to remove any contaminating DNA. One aliquot of the RNA was reverse transcribed with SuperScript II (Life Technologies) using random hexamer primers. Another aliquot of the RNA was treated in the same way but in the absence of the reverse transcriptase. This sample served as a control for genomic contamination in subsequent PCR reactions.
Samples of the cDNA were initially amplified by PCR with primers to glyceraldehyde-3-phosphate dehydrogenase to verify the integrity and relative quantity of cDNA. Each 50-µl PCR reaction used 5% of the cDNA obtained from reverse transcription reactions, representing total mRNA from 5-10 mm (equivalent to ϳ4,000 to 8,000 cells) of the microdissected tubules. Specific primers were designed for the rat dopamine D 1A and D 4 receptor isoforms based on their published sequences (25, 44) . As shown in Fig. 1 , we used three primer pairs to amplify D 4 regions covering most of the coding sequence: Transmembrane 2 (tm2) to tm3, the second cytoplasmic loop (c2) to tm5, and c3 to tm7, respectively. Each primer set spanned an intron to ensure genomic DNA was not amplified. (Note that extracted RNA samples were also treated with DNase I.) Two primer pairs were designed for the D 1A dopamine receptor (Fig. 1, bottom) : 1) tm7 into the 3Ј-untranslated region and 2) the third cytoplasmic loop (tm5 to tm6). The D 1A coding region has a single short intron in the 5Ј-untranslated region (not shown in Fig. 1 ), which was not reported in the original sequence but which was identified subsequently (22, 44, 45) . The PCR products were initially verified by restriction enzyme mapping (Table 1 ) and subsequently by sequencing.
PCR reaction mixtures contained 2.5 mM MgCl 2 , 50 mM KCl, 20 mM Tris · HCl (pH 8.4), 1.7% BSA, 0.05 mM of each deoxynucleoside 5Ј-triphosphate, 25 pmol of each oligonucleotide primer, and 1 U of Taq DNA polymerase (Promega, Madison, WI; and Fisher Scientific, Pittsburgh, PA) per 50 µl of total reaction volume. To amplify dopamine receptor cDNA, we used 48 cycles (94°C for 1 min, 60°C for 1 min, and 72°C for 1 min) followed by a final 7-min extension at 72°C. When PCR products were to be cloned into the pCR 2.1 plasmid (see below), extension at 72°C was increased to 60 min to increase cloning efficiency (17) . The PCR products were resolved on a 2% agarose gel. For restriction analysis, PCR products were ethanol precipitated, then resuspended in sterile water. Purified products were digested with the restriction endonucleases (Table 1) according to the manufacturer's instructions.
When the presence of an isoform was indicated by restriction enzyme analysis, the PCR product was cloned into the plasmid vector pCR 2.1 by TA cloning (Invitrogen, San Diego, CA) according to manufacturer's instructions. Bidirectional sequence analysis was performed using the T7 and M13 universal primers and dye-termination reactions at the University of Alabama DNA Sequencing Core Facility (Dr. S. Hollingshead, Director). The sequences were aligned with the appropriate GenBank sequences using the GAP program of the Wisconsin Sequence Analysis Package (version 8; Genetics Computer Group, Madison, WI).
Antibodies for immunoblotting and immunohistochemistry of D 4 The D 1A receptor antibody was a generous gift from Dr. Robert M. Carey (Univ. of Virginia, Charlottesville, VA). Carey and his associates (24) raised this rabbit polyclonal antibody against amino acids 299-307 corresponding to most of the third extracellular loop of the rat receptor. They carefully confirmed the specificity of the antibody (using the IgG serum fraction, without affinity purification) by demonstrating selective labeling in fibroblasts (cell line LTK Ϫ ) stably transfected with the D 1A message in comparison with nontransfected cells, and they also showed specific localization of binding in rat brain sections (24) . We also examined a second antibody (catalog no. D1DR; Santa Cruz Biotechnology, Santa Cruz, CA), which was raised in goat against the 20 COOH-terminal amino acids of the human D 1 receptor, which is identical to the rat D 1A receptor in this region. Using protein extracted from rat kidney, heart, or brain, however, we could not obtain specific immunoblotting with either of two separate lots of this antibody. In these unsuccessful attempts, we first tried the blocking procedure and secondary biotinylated rabbit anti-goat IgG as recommended by the manufacturers. We then tried a variety of alternative blocking procedures, all without success. Thus the results reported here are those obtained using the D 1A antibody from Dr. Carey and the D 4 antibody from R & D Antibodies.
Protein extraction and immunoblotting. The heart and the opposite kidney were removed from some of the rats used for CCD microdissection and RT-PCR. The tissues were homogenized with a Tissue Tearor (model 985-370, type 2; Bartlesville, OK) in 3 ml/g of extraction buffer (20 mM Tris · HCl, pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton X-100, and 25 µg/ml each of aprotinin and leupeptin), and incubated on ice for 20 min. The supernatant was retained after centrifugation at 12,000 rpm for 20 min, and the protein concentration was determined by Micro BCA protein assay (Pierce Chemical, Rockford, IL). Extracted proteins were resolved by electrophoresis on an 8% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and stained with Ponceau S for molecular weight marker localization. The membrane was blocked overnight at 4°C in Blotto, consisting of 5% nonfat dried milk (NFDM) and 0.025% Tween 20 in Tris-buffered saline (TBS, pH 7.4). The membrane was then incubated overnight with the D 4 antibody (see above) diluted 1:2,000 in Blotto. After three 10-min washes with TBS containing 0.025% Tween 20 (T-TBS), the membrane was incubated for 1 h at 25°C in a 1:6,000 dilution in Blotto of donkey anti-rabbit IgG linked to horseradish peroxidase. Following three 10-min washes in T-TBS, the membrane was incubated with enhanced chemiluminescence substrate (ECL; Amersham, Arlington Heights, IL) and exposed to autoradiography X-ray film.
Immunohistochemistry. Rat kidneys were removed quickly, sliced in 1-to 2-mm thick coronal sections, and fixed with 4% ultrapure formaldehyde in PBS (pH 7.4). Slices were embedded in paraffin, and 4-µm sections were cut and mounted on slides. The slides were incubated at 56°C overnight, deparaffinized with xylene, and rehydrated in a graded series of ethanol solutions. Endogenous peroxidase was blocked by 0.3% H 2 O 2 in methanol for 30 min at room temperature. For the D 4 antibody, nonspecific staining was blocked with 3% normal goat serum (NGS) in PBS for 20 min at room temperature. For the D 1A antibody, we blocked with 3% NGS plus 1% NFDM in Tris buffer (pH 7.2) as described by O'Connell et al. (24) . (This procedure was also found to be a satisfactory alternative blocking procedure for D 4 immunoblotting.) After removing the blocking solution, the sections were incubated with dilutions of the D 4 antibody (1:500 to 1:2,000 in PBS containing 2% NGS) for 30 min or of the D 1A antibody (1:5 to 1:2,000 in PBS with 1% NGS plus 0.5% NFDM) for 2 h. The slides were washed twice with PBS, and the primary antibody was detected with biotinylated goat anti-rabbit IgG using an immunoperoxidase reaction (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) according to the kit instructions. Antibody localization was visualized using diaminobenzidine as the substrate for peroxidase color development and light hematoxylin counterstain. The sections were then dehydrated, and cover slips were permanently mounted. The specificity of the immunolabeling was confirmed by controls: 1) incubation without primary antibody and 2) incubation without secondary antibody.
Measurement of V T in isolated perfused CCD. For these experiments, CCD segments were dissected from kidneys without collagenase treatment and were perfused in vitro using an isotonic artificial bathing solution similar to rat serum and a hypotonic perfusate resembling early distal tubular fluid. [Methoxy-3 H]inulin was added to the perfusate as the volume marker. Perfusion at 10 to 20 nl/min was carried out at 38°C. V T was measured between Ag/AgCl electrodes in the perfusate and bathing solution and was recorded continuously on a strip chart recorder.
Sources of other biochemicals. Amplification grade DNase I (catalog no. 18068) and SuperScript II reverse transcriptase (catalog no. 188064-014) were from Life Technologies (Gaithersburg, MD). Oligonucleotide primers were from Integrated DNA Technologies (Coralville, IA) and Oligos Etc. (Guilford, CT). Restriction endonucleases Acc I and Ava I were from New England Biolabs (Beverly, MA) and Ava II, Ban I, Ban II, Nru I, and Pvu II were from Promega. Protein molecular weight standards were from Bio-Rad Laboratories (Hercules, CA; high-range standards, catalog no. 161-0303).
RESULTS
RT-PCR analyses were conducted for dopamine D 1A and D 4 isoforms in the rat CCD with, respectively, seven and eight separate groups of CCD from which RNA was extracted. Based on previous results in isolated, perfused CCD in our laboratory (37) and in nonperfused CCD segments in the laboratory of Katz and colleagues (30, 31, 32) , mRNA for both D 1A and D 4 dopamine receptors was expected to be present. In our early experiments, in which RNA was extracted from Ͻ20 mm of CCD, we detected either isoform only infrequently. In subsequent studies, we extracted RNA from 100-200 mm of CCD, and thus RNA from ϳ4,000 to 8,000 cells was amplified. As summarized in Table 2 , single PCR products of the expected size were readily observed for both isoforms, with a single exception in the case of each.
The first set of D 4 primers (161-bp product, Table 1 ) restricted as anticipated with Acc I and Ban II and was detected in CCDs in seven of eight RNA extractions. The PCR product was cloned into the pCR 2.1 plasmid vector, and bidirectional sequence analysis indicated 100% nucleotide identity with the published sequence from rat atria (25); however, there was an additional 6-bp (GTCCAG) insert within our PCR product precisely at the site of the first intron. As shown in Fig. 2 , our PCR sequence is identical to the mouse and human D 4 receptor sequences in this region, and our 6-bp sequence matches the beginning of exon 2 in those species (9, 40) . Our sequence was also confirmed by the fact that the extra six bases introduce an Ava II restriction site in the PCR product, and we obtained products of the size predicted by the human and mouse sequences (9, 40) . We used the same primer pair to amplify cDNA from rat atria and brain and confirmed the presence of the same 6-bp insert by Ava II restriction and sequence analysis (data not shown). In the rat sequence published by O'Malley et al. (25) , the same nucleotide sequence was included as the ending of the first intron, but subsequent sequencing of the rat D 4 cDNA by Dr. O'Malley's laboratory revealed the presence of the same additional 6 bases (personal communication) in the exon (see DISCUSSION) .
The second set of D 4 receptor primers produced the expected 346-bp product, corresponding to the region from c3 to tm7, which restricted with Ava I, Ban I and Pst I. Identity of the PCR product was verified by bidirectional sequencing. The third set of primers produced the expected 213-bp product, from the c2 to the tm5 region, which restricted as predicted with Acc I, Nru I, and Pvu II (Fig. 3) , and was verified by bidirectional sequencing.
In experiments with the first set of D 1A receptor primers, the 527-bp product, corresponding to nucleotides from tm7 to the 3Ј-untranslated region, restricted with Ava I and Ban II (Fig. 4) as anticipated from the published sequence, and was detected in four of four experiments. The second primer set, corresponding to the third cytoplasmic loop (tm5-tm6) of the D 1A recep- Results are expressed as number of experiments in which the dopamine receptor isoform was detected compared to the total number of groups of cortical collecting ducts (CCD) from which RNA was extracted. Each group consisted of Ն100 mm of microdissected CCD segments, and 5-10% of the total cDNA obtained from reverse transcription was amplified (see text). We initially attempted to confirm the presence of both receptors at the protein level by immunoblotting of protein extracted from microdissected CCD segments. Extraction of 100 mm of CCD yields slightly more than 10 µg of protein, and we have been successful in using such samples to demonstrate the presence of specific protein kinase C isoform proteins in the rat and rabbit CCD (41) . However, despite repeated attempts using a variety of antibody dilutions, and blocking and development procedures, we were unable to obtain acceptable immunoblots of protein extracted from 100-140 mm of CCD segments using the D 4 antibody. (We did not examine the D 1A antibody from Dr. Carey, because its specificity had already been confirmed.) However, using protein extracted from rat heart, which has a 20-fold higher expression of the D 4 receptor mRNA than other tissues (24) , and a greater amount of total protein extracted from whole rat kidney cortex than could be obtained from the microdissected CCD segments, the D 4 antibody reacted strongly with a band of the expected 41-42 kDa size of the nonglycosylated protein as shown in Fig. 5 . There was also a heavy band of 58-59 kDa and a very faint band of ϳ48 kDa in the heart protein, but only the heavier band was present in the kidney cortex. Labeling of all three bands was blocked by preadsorption of the antibody to its antigenic peptide. Because the D 4 receptor protein has a glycosylation site, it is likely that the heavier band represents the glycosylated form of the protein and that this is the primary form found in the kidney cortex.
We then used this D 4 antibody and the D 1A antibody from Dr. Carey for immunohistochemistry on coronal slices of rat kidney. We found that the latter antibody labeled the tissue as described by O'Connell et al. (24) . Labeling was observed primarily in the cortex and not the medulla. The cortical labeling was diffuse and light throughout proximal tubules, distal tubules, and CCD (data not shown). In contrast, the D 4 antibody labeled exclusively in the medulla and medullary rays in the cortex, where it is was specific to CCD segments and to (25) and with the published mouse and human sequences (9, 40) . Regions of difference among the sequences are given in the 2 boxes. The amino acid sequence is given in the last line. In all 3 of the previously published genomic sequences, there is an intron near the end of the second transmembrane region (underlined nucleotides) as indicated by the arrow. The sequence of the PCR product obtained in our experiments is identical in the region shown to the mouse and human sequences (with the exception of the C-for-T substitution in the human sequence that results in a conservative alanine-for-valine amino acid substitution). (Fig.  6, A and B) . No staining was seen in any other segments. At high magnification (Fig. 6C) , it appeared that the immunoreactivity was greater on the luminal surface than on the basolateral membrane.
In our previous studies (37), we had examined the functional effects of dopamine only when added to the bathing solution of isolated perfused rat CCD and not the lumen. Because of the apparent localization of immunoreactive D 4 protein on the luminal membrane, we conducted a series of experiments in which we examined the effect of luminal dopamine on V T . In the five experiments shown in Fig. 7 , AVP produced a significant hyperpolarization of V T in the CCD from DOC-treated rats; however, the further addition of 100 µM dopamine to the luminal perfusate had no significant effect. Addition of 10 µM dopamine to the bathing solution significantly depolarized V T , and the effect was reversed by the further addition of 10 µM clozapine to the bathing solution as reported previously (37) . Finally, the removal of dopamine and clozapine from the bathing solution, thus returning to the conditions of the second period, had no effect on V T . In summary, the only effect of dopamine on V T was observed when it was added to the bathing solution, and that effect was reversed by clozapine.
DISCUSSION
The data presented above demonstrate the presence of mRNA for both the D 1A and D 4 dopamine receptor isoforms in the rat CCD (Table 2 ) and of protein immunoreactive with a D 4 antibody in the CCD and medullary collecting duct (Figs. 5 and 6 ). We also observed labeling of all cortical nephron segments with the D 1A antibody as described by O'Connell et al. (24) . Other investigators have demonstrated the presence of D 1 -type and specific D 1A and D 2 receptors by binding studies and RT-PCR of digests of rat renal cortex and medulla (10, 21, 25) , as well as in microdissected and sieved rat proximal tubules and juxtaglomerular cells (8, 42, 43) . A D 1 -type receptor has also been found by binding studies in the rat CCD (39) . RT-PCR has also revealed D 3 and D 4 receptor isoform mRNA in rat juxtaglomerular cells (29) and the D 4 isoform in human kidney mRNA (20) . The fact that we had to use a relatively large sample of CCD segments to observe expression of either the D 1A or D 4 isoform by RT-PCR suggests that the mRNA is present in low copy number. This would also explain why the D 4 isoform was not observed by Northern blot analysis of RNA from whole kidney, especially considering that the isoform is confined to the CCD and medullary collecting duct (see Fig. 6 ).
We expected that the age of the rats used in these studies (5-7 wk) was appropriate for detecting at least the D 1A receptor. Kansra et al. (15) reported that there is a ϳ50% decrease in renal D 1A receptor density in old (23-24 mo) rats compared with adult rats (6 mo), and that there was also decreased expression of receptorlinked G protein in the older rats. Felder et al. (8) reported that there was no age-related difference in the maximum D 1 receptor density in proximal convoluted tubules from SHR and WKY rats examined at 3, 8, and 20 wk of age; however, there was an increase in dopamine-stimulated adenylyl cyclase activity and in the natriuretic effect of dopamine with age in the WKY rats. If the D 4 receptor density also declines with age, then this may explain why our functional studies with CCD from young rats have indicated the presence of this receptor (37) , whereas there is no functional evidence for its presence in other studies in which older animals were used (e.g., Refs. 30, 38) .
Sequencing with the first set of D 4 primers showed an extra 6 bp in comparison with the published rat D 4 sequence (25), corresponding to the beginning of the second exon in the mouse and human sequences (Fig.  2) . Sequencing of the RT-PCR products from rat atria and brain RNA also showed the same 6-bp insert. We have since learned from Dr. K. O'Malley (personal communication) that her group has examined rat D 4 cDNA, and they also observed this 6-bp insert, which was originally overlooked, probably as the consequence Immunohistochemistry supported the presence of the D 4 receptor isoform in the CCD and also in the medullary collecting duct (Fig. 6) . We verified the specificity of the D 4 antibody by immunoblotting (Fig.  5) , and we also supplied a sample of the same lot of the antibody to Dr. K. O'Malley (Washington Univ., St. Louis, MO) for additional testing. Dr. O'Malley's laboratory found (personal communication) that the antibody stained structures in the retina, primarily in the inner nuclear layer, in a pattern which was similar to that which they observed previously for the D 4 receptor mRNA by in situ hybridization (5) . (The D 4 receptor in the retina has been demonstrated to be coupled to the modulation of the dark level of light-sensitive cAMP production in photoreceptors; Ref. 5) . O'Malley's group (personal communication) also found that our D 4 antibody labeled a ϳ41-kDa protein on immunoblot analysis of proteins extracted from a cell line that had been stably transfected with the D 4 receptor message, but did not react with proteins from nontransfected cells.
Cortical labeling was seen only in the medullary rays and was associated exclusively with the CCD. Labeling of the medullary collecting duct was, if anything, more dense than in the CCD, and the entire length of the collecting duct showed the presence of the receptor. Maeda et al. (19) have examined the effect of dopamine of AVP-dependent cAMP production in a limited num- http://ajprenal.physiology.org/ ber (n ϭ 3) of inner medullary collecting duct (IMCD) segments. Although they found no effect of dopamine at 0.01 or 1 µM, 100 µM produced a significant inhibition of cAMP production in the presence of 100 pM AVP. Maeda et al. (19) suggested that the effect of such a high dose might have been mediated by the ␣ 2 -adrenergic receptors that they observed in the IMCD in the same study; however, they did not test the effect of concentrations in the range of 1-10 µM that we have found to be the most effective (16, 37) .
It was puzzling that in both the cortex and the medulla the labeling with the D 4 antibody appeared to be heavier on the luminal surface than on the basolateral surface. For that reason, we undertook experiments with isolated perfused CCD to see whether we could obtain an effect of luminal dopamine. As shown in Fig. 7 , we were unable to detect any inhibition of AVP-dependent V T in these experiments, so the function of the luminal receptors remains unclear.
The effects of dopamine on the distal regions of the nephron have been a matter of controversy. Muto et al. (23) showed that dopamine inhibited AVP-stimulated osmotic water permeability in the isolated perfused rabbit CCD presumably by a D 2 -type receptor. On the other hand, Satoh et al. (30, 31, 32) have shown that dopamine decreases Na-K-ATPase activity in nonperfused rat CCD segments via a D 1 -type receptor, which increases the production of cAMP and activates protein kinase A. Despite the fact that dopamine appears to decrease Na-K-ATPase activity in the basolateral membrane, it seems improbable to us that dopamine could inhibit transepithelial Na ϩ transport by such a mechanism, because AVP is known to stimulate Na ϩ reabsorption in the rat CCD by increasing intracellular cAMP, which thereby increases the Na ϩ conductance of the luminal membrane (4, 28, 33, 35) . Thus it would seem that any effect of dopamine to decrease Na-K-ATPase activity through a D 1A receptor is superseded by the effect of cAMP on the luminal membrane Na ϩ channels.
As discussed in the introduction, we have demonstrated that dopamine inhibited the Na ϩ and water transport in isolated perfused rat CCD and the inhibition was mediated by a D 4 -like receptor (37) . In more recent experiments (16), we also examined the effect of dopamine and fenoldopam on cAMP generation in microdissected, intact CCD segments. We found that neither fenoldopam nor dopamine had any significant effect on cAMP generation in the absence of AVP. However, when cAMP generation was increased by AVP, dopamine but not fenoldopam inhibited this increase, and this effect was reversed by 10 µM clozapine (16) . Clozapine also has limited affinity for serotonin (5-HT) receptors; however, the 5-HT 1 subgroup of these receptors, the subgroup that inhibits cAMP production, is not affected by dopamine.
There are two caveats to our interpretation of these results. First, our studies were conducted in young (5-to 7-wk-old) rats. Although Felder et al. (8) observed no difference in D 1A receptor density in proximal tubules from the WKY rat, they did observe diminished cAMP production in response to dopamine in the younger rats, which might explain our inability to demonstrate an increase in cAMP generation with fenoldopam or dopamine. The second caveat is that the CCD used in our previous studies with isolated perfused segments came primarily from DOC-treated rats (37) . One set of experiments in that study did examine CCD from rats that were untreated with DOC and showed the same pattern of response to dopamine and clozapine, with no effect of fenoldopam. Our studies on cAMP production were also conducted on CCD from rats receiving no DOC treatment (16) , as were all of the experiments in the present study, with the exception of those reported in Fig. 7 .
It is also possible that the D 4 receptors could also be associated with alternative intracellular coupling mechanisms. Although the D 4 receptor has been linked to inhibition of adenylyl cyclase (5) (26) . It seems unlikely, however, that this is the mechanism of dopamine action in the rat CCD. Quinpirole has no effect on transepithelial transport process stimulated by AVP (37), and we have found that prostaglandin E 2 is not inhibitory to either Na ϩ transport or water permeability in the rat CCD (3) .
Based on the present data as well as our past studies, (16, 37), we conclude that both the D 1A and D 4 dopamine receptors are expressed in the rat CCD. The effects mediated by the D 1A receptor have been observed only in nonperfused preparations in which transepithelial transport was not measured, and any effects of this receptor do not override the effect of dopamine on transepithelial transport in the presence of AVP. Thus we conclude from the current data and previous functional studies (16, 37) that the diuretic and natriuretic effects of dopamine in the CCD are primarily mediated by the D 4 receptor.
